Menu Close

Nohla Therapeutics Receives FDA Orphan Drug Designation for Dilanubicel for Hematopoietic Stem Cell Transplant Patients

“Dilanubicel has shown encouraging initial activity as a novel cell therapy in patients with hematologic malignancies receiving a cord blood transplant,” said Katie Fanning, President and CEO of Nohla Therapeutics. “We believe the addition of …

뉴스 수집 시각 : 2018-07-16T18:19:00.000Z
뉴스 본문 보기 : https://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=283876